Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. - Wikidata - wikimedia - TriplyDB

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.

http://www.wikidata.org/entity/Q35819025

about

Decreased plasma levels of soluble CD18 link leukocyte infiltration with disease activity in spondyloarthritis Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies Making the next steps in psoriatic arthritis management: current status and future directions Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies The Changing Face of Clinical Trials in Psoriatic Arthritis.Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: A review.Use of biologic agents in combination with other therapies for the treatment of psoriasis Methotrexate toxicity during treatment of chronic plaque psoriasis: a case report and review of the literature.Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials.Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials.Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis.Steps in the management of psoriatic arthritis: a guide for clinicians.Assessment of the Therapeutic Aspect of Systemic Non-Biologic Anti-Psoriatic Treatment Modalities Used in Combination with Methotrexate.Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases.Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis.Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.Psoriatic arthritis: current therapy and future directions.Ustekinumab : targeting the IL-17 pathway to improve outcomes in psoriatic arthritis.Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety.Apremilast for the treatment of psoriatic arthritis.A systematic review on the efficacy and safety of Infliximab in patients with psoriasis.Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis.European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis.Inflammation and the Silent Sequelae of Stroke.Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.New developments in our understanding of psoriatic arthritis and their impact on the diagnosis and clinical management of the disease.Efficacy and safety of infliximab in psoriatic patients over the age of 65.Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.Hit hard and early: Can the march of psoriasis be halted?Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: A meta-analysis of randomized controlled trials.Efficacy of Anti-TNF Agents as Adjunctive Therapy for Knee Synovitis Refractory to Disease-Modifying Antirheumatic Drugs in Patients with Peripheral Spondyloarthritis.Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate.Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence.Use of Immunosuppressive Medications for Treatment of Pediatric Intermediate Uveitis.Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis.[Psoriatic arthritis : Overview of drug therapy options and administration characteristics].[Psoriatic arthritis : Overview of drug therapy options and administration characteristics].Spondyloarthritis: Is methotrexate effective in psoriatic arthritis?

P2860

Q22000831-CA63E7F8-8AB9-431F-8FFD-7DFAE6F5A628 Q26764867-9F1B9025-E9AA-4E68-B283-43B3F3979520 Q26783506-B2AC707A-37F3-4E18-8874-2D71A5AD8850 Q26991673-DBC6053D-D08A-4FA7-BCFE-96F67CDAFEAB Q30235002-0776176E-86E7-4F4C-BA7B-3D1783498224 Q30240183-907D4D61-E709-4117-BB0C-DB2C9B3A3902 Q30251926-3683CED0-CCA9-4B25-A382-2A76EBEF0CD5 Q34553755-26E08AFA-C6D1-4613-88E6-47843F04C2E7 Q34642567-CD04AE7B-29BE-4145-B5DA-79BF98A744A5 Q36014642-53E2531B-1F7D-46E0-BC45-D499EE90714E Q36321264-9C7B620B-2878-44B6-986E-F21B780500A0 Q36479450-B8A178EA-E00D-4697-9C1B-51E4A74290E9 Q36515480-F7A6F3C3-6587-4732-94FC-A8058BBD49D5 Q36607070-6A968EDB-0382-4D66-BB19-E0D2BE8453FA Q36923514-855F818B-FF71-48A0-9655-5BE2F8A60B22 Q37520856-E7C21704-02B6-420D-B2BB-281EB955099E Q38098466-59BE50B0-974D-4B2A-8FAF-1CFCACF6B235 Q38118343-4FF51651-FAFF-48D3-90E5-3BF7225C2140 Q38189853-F968D9BD-EEB7-4CD8-81F5-AB01B82087F5 Q38204241-0B56AB52-9777-448A-AA21-519C84CB90EA Q38616811-D4FB4176-19A2-451C-BF6D-3D3DE69ECD89 Q38623340-69670167-375E-4ECE-ABA4-EED3E82A91AD Q38630548-D2727574-E97A-4316-BE2C-FF58B92042B6 Q38661777-DE46F28B-CC0A-48AF-A624-AA63FF935A73 Q38667430-0C83393F-90E1-4830-BF20-244EB5CC8656 Q38871034-12F6012D-98E5-4AD5-92E8-D099EEAFB02B Q39004045-DD8F70C5-4634-43B6-8419-543655CEEB1D Q39373505-DB3A7410-26A9-41EB-AB32-22EF96DACE9D Q39480582-D550C1B4-9BA4-4008-9E39-F7F254E14876 Q41615511-6D9AECE2-3386-473E-BF08-BE872EA3AA32 Q41848576-5522C793-071E-49E8-9B28-43984C6A2DE2 Q42376342-CF62D117-BDAA-4850-9EC9-268EE011153B Q43115288-3F862F1B-72D8-4249-AC87-9D47D35B442C Q43641073-D0FC5CF9-9213-4FD9-A36A-DB63DE0FDAE5 Q47114261-EDE141AD-4D16-4FFD-A5EC-6EAF3789E9BB Q47608437-798AEF5E-DEA6-44A8-BAF2-C12C60740B90 Q51040429-91AF9017-BF0A-4598-A7E0-93171AB1EA66 Q52927228-B769E542-82E8-4F9B-AC4C-472EFC7AB3AD Q53760739-E1F84E3E-2288-438D-BFDA-A6D3D53662C8 Q54162420-9121C10D-5D47-4F3E-BBE9-2460EBBC6C53

P2860

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.

http://www.wikidata.org/entity/Q35819025

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Infliximab plus methotrexate i ...... e patients: the RESPOND study.

@ast

Infliximab plus methotrexate i ...... e patients: the RESPOND study.

@en

type

label

Infliximab plus methotrexate i ...... e patients: the RESPOND study.

@ast

Infliximab plus methotrexate i ...... e patients: the RESPOND study.

@en

prefLabel

Infliximab plus methotrexate i ...... e patients: the RESPOND study.

@ast

Infliximab plus methotrexate i ...... e patients: the RESPOND study.

@en

P1433

Q35819025-88E12438-69A7-4269-A2AD-40CBCC6DACF4

P1476

Q35819025-2FD76151-57B2-4B31-96CC-42693216BF04

P2093

Q35819025-08F69A0B-9181-4762-9BC4-C1F78B996221

Q35819025-13F96488-BF6C-464D-ACC5-36F78AE6E1F6

Q35819025-22E8B6BD-B3AE-472E-868C-2291CEF697F0

Q35819025-29643E58-28C9-49DA-B230-18C272834121

Q35819025-659C0D0B-139E-4580-92C6-7AA729902A52

Q35819025-682D961C-C9F3-491A-A08B-478E89413BF8

Q35819025-805DDEC6-882B-43ED-9F13-CE746CDB3B4C

Q35819025-E1E08772-2995-4BD4-9EBB-FB2EE3012794

Q35819025-EE143501-7B5C-41BD-8F57-B1F5B76ACFB0

P2860

Q35819025-16EC8E6A-DD9A-44A4-AFED-AFB7B8683C2D

Q35819025-2B594EA1-5FAB-40FE-95F8-13DAAC0C6B79

Q35819025-2CA534F9-0430-400D-9526-6AEEB81C0ED9

Q35819025-469212FC-0072-40D6-9FA2-990E8FF4D771

Q35819025-625F2374-280A-4AB2-9C4D-FF45EC5EEB41

Q35819025-6A5CABD5-1AF3-48EB-8A0E-9022AFF68E4D

Q35819025-6F717251-99EE-4DE8-A45C-A49A504EC2E9

Q35819025-70FD9A0E-AE82-4BDB-BDFF-241874C7473C

Q35819025-92E5672B-2CA9-44DB-A464-2725473267E2

Q35819025-ABC43A19-AEEF-495E-89B6-2D57D36328F0

P304

Q35819025-AEDF69CF-5259-4F5B-B2D2-A319DEA381AE

P31

Q35819025-980CC32E-EF44-45F8-94C3-42468B2854EE

P356

Q35819025-39CCEDBE-B412-4F85-B84C-1454474829B1

P407

Q35819025-F2102728-5908-498B-B1B1-37EC6F8D5AEB

P433

Q35819025-70882941-0A2F-42BE-AA56-B3A82AC34E41

P478

Q35819025-7D7DFE25-7A55-4570-B74B-85B2204F76E9

P50

Q35819025-CFD74F2D-0700-45A0-A6B6-3E2D12C08C6A

P577

Q35819025-1ED4BF6A-9C59-4BDB-8CED-2D0A5B71F7AE

P5875

Q35819025-36416889-3D4E-4016-A797-7568580AFEE9

P698

Q35819025-F410ED0B-29AA-434C-8323-87E62B3CC74E

P921

Q35819025-7F2ACFE3-3285-4454-9EB9-7626ABE68375

P932

Q35819025-EAD5D01A-1F6A-4E3F-938E-B0F0E80729B3

P356

ARD.2011.152223

P1433

Annals of the Rheumatic Diseases

P1476

Infliximab plus methotrexate i ...... ve patients: the RESPOND study

@en

P2093

Algirdas Venalis

http://www.w3.org/2001/XMLSchema#string

Anna Kubanova

http://www.w3.org/2001/XMLSchema#string

Asta Baranauskaite

http://www.w3.org/2001/XMLSchema#string

Evgeny Nasonov

http://www.w3.org/2001/XMLSchema#string

Helena Raffayová

http://www.w3.org/2001/XMLSchema#string

Laszlo Helmle

http://www.w3.org/2001/XMLSchema#string

N V Kungurov

http://www.w3.org/2001/XMLSchema#string

Nathan Vastesaeger

http://www.w3.org/2001/XMLSchema#string

Shankar Srinivasan

http://www.w3.org/2001/XMLSchema#string

P2860

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey.

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.

Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.

Treatment recommendations for psoriatic arthritis.

Mortality in psoriatic arthritis.

Psoriatic arthritis from Wright's era until today.

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.

P304

541-548

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2011.152223

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

RESPOND investigators

P577

2011-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51711766

http://www.w3.org/2001/XMLSchema#string

P698

21994233

http://www.w3.org/2001/XMLSchema#string

P921

P932

3298666

http://www.w3.org/2001/XMLSchema#string